NASDAQ:VXRT Vaxart (VXRT) Stock Forecast, Price & News $0.85 -0.05 (-5.57%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.83▼$0.9150-Day Range$0.60▼$1.4152-Week Range$0.56▼$4.62Volume4.05 million shsAverage Volume1.77 million shsMarket Capitalization$115.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaxart MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside460.0% Upside$4.75 Price TargetShort InterestBearish13.80% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.70) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector841st out of 986 stocksBiological Products, Except Diagnostic Industry136th out of 161 stocks 3.3 Analyst's Opinion Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Vaxart has a forecasted upside of 460.0% from its current price of $0.85.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.80% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxart has recently decreased by 1.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VXRT. Previous Next 2.4 News and Social Media Coverage News SentimentVaxart has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Vaxart this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows11 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 38.66% of the stock of Vaxart is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.70) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaxart (NASDAQ:VXRT) StockVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.Read More Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesJune 7, 2023 | marketwatch.comVaxart Shares Sink 27% on Offering PricingJune 7, 2023 | finance.yahoo.comVaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common StockJune 9, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>June 7, 2023 | investorplace.comWhy Is Vaxart (VXRT) Stock Down 25% Today?June 6, 2023 | finance.yahoo.comVaxart, Inc. Announces Proposed Public Offering of Common StockJune 6, 2023 | finance.yahoo.comVaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus CandidateMay 31, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Vaxart's (NASDAQ:VXRT) Cash Burn SituationMay 31, 2023 | finance.yahoo.comVaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ETJune 9, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 17, 2023 | americanbankingnews.comVaxart, Inc. to Post FY2023 Earnings of ($0.65) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:VXRT)May 11, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Vaxart, Inc.'s Q2 2023 Earnings (NASDAQ:VXRT)May 4, 2023 | finance.yahoo.comVaxart Provides Business Update and Reports First Quarter 2023 Financial ResultsApril 28, 2023 | finance.yahoo.comVaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4March 29, 2023 | finance.yahoo.comVaxart to Present at World Vaccine Congress Washington 2023 on April 5-6March 21, 2023 | americanbankingnews.comFY2023 Earnings Estimate for Vaxart, Inc. Issued By Jefferies Financial Group (NASDAQ:VXRT)March 18, 2023 | finance.yahoo.comVaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | finance.yahoo.comVaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for NorovirusMarch 15, 2023 | finance.yahoo.comVaxart Provides Business Update and Full Year 2022 Financial ResultsMarch 8, 2023 | finance.yahoo.comVaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15February 14, 2023 | finance.yahoo.comVaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus CandidateDecember 19, 2022 | finance.yahoo.comVaxart Names Phillip Lee as Chief Financial OfficerDecember 1, 2022 | finance.yahoo.comVaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding MothersDecember 1, 2022 | finance.yahoo.comVaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding MothersNovember 22, 2022 | finance.yahoo.comVaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29November 11, 2022 | finance.yahoo.comVaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)November 8, 2022 | finance.yahoo.comVaxart Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comVAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue EstimatesSee More Headlines VXRT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VXRT Company Calendar Last Earnings3/15/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees110Year Founded2004Price Target and Rating Average Stock Price Forecast$4.75 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+462.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,760,000.00 Net MarginsN/A Pretax Margin-15,454.95% Return on Equity-92.58% Return on Assets-67.32% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio4.84 Sales & Book Value Annual Sales$697,000.00 Price / Sales164.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book1.00Miscellaneous Outstanding Shares135,597,000Free Float131,529,000Market Cap$114.44 million OptionableNot Optionable Beta0.78 Social Links Key ExecutivesAndrei FloroiuPresident, Chief Executive Officer & DirectorPhillip Eric LeeChief Financial OfficerSean N. TuckerChief Scientific Officer & Senior Vice PresidentJames F. CummingsChief Medical OfficerRaymond D. StapletonChief Technology OfficerKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPGamida CellNASDAQ:GMDAC4 TherapeuticsNASDAQ:CCCCGraphite BioNASDAQ:GRPHJasper TherapeuticsNASDAQ:JSPRView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 28,403 shares on 5/18/2023Ownership: 0.073%Geode Capital Management LLCBought 82,949 shares on 5/16/2023Ownership: 1.964%State Street CorpBought 255,355 shares on 5/16/2023Ownership: 1.957%Susquehanna International Group LLPBought 600 shares on 5/16/2023Ownership: 0.000%IHT Wealth Management LLCSold 7,644 shares on 5/15/2023Ownership: 0.193%View All Insider TransactionsView All Institutional Transactions VXRT Stock - Frequently Asked Questions Should I buy or sell Vaxart stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares. View VXRT analyst ratings or view top-rated stocks. What is Vaxart's stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price objectives for Vaxart's shares. Their VXRT share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 462.8% from the stock's current price. View analysts price targets for VXRT or view top-rated stocks among Wall Street analysts. How have VXRT shares performed in 2023? Vaxart's stock was trading at $0.9609 at the beginning of 2023. Since then, VXRT stock has decreased by 12.2% and is now trading at $0.8440. View the best growth stocks for 2023 here. When is Vaxart's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our VXRT earnings forecast. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) issued its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.15 million. What ETFs hold Vaxart's stock? ETFs with the largest weight of Vaxart (NASDAQ:VXRT) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM). When did Vaxart's stock split? Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), Organigram (OGI) and Novan (NOVN). What is Vaxart's stock symbol? Vaxart trades on the NASDAQ under the ticker symbol "VXRT." Who are Vaxart's major shareholders? Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.50%), Geode Capital Management LLC (1.96%), State Street Corp (1.96%), Two Sigma Investments LP (0.88%), Two Sigma Advisers LP (0.81%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Armistice Capital, Llc, Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaxart's stock price today? One share of VXRT stock can currently be purchased for approximately $0.84. How much money does Vaxart make? Vaxart (NASDAQ:VXRT) has a market capitalization of $114.44 million and generates $697,000.00 in revenue each year. The biotechnology company earns $-107,760,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does Vaxart have? The company employs 110 workers across the globe. How can I contact Vaxart? Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580. This page (NASDAQ:VXRT) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.